Edition:
India

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

8.35USD
2:29am IST
Change (% chg)

$-1.10 (-11.64%)
Prev Close
$9.45
Open
$9.35
Day's High
$9.35
Day's Low
$8.12
Volume
284,688
Avg. Vol
132,132
52-wk High
$29.35
52-wk Low
$8.12

Latest Key Developments (Source: Significant Developments)

Coherus Biosciences Q3 loss per share $1.09
Tuesday, 7 Nov 2017 

Nov 6 (Reuters) - Coherus Biosciences Inc :Coherus Biosciences reports third quarter 2017 operating and financial results.Q3 loss per share $1.09.Q3 earnings per share view $-0.81 -- Thomson Reuters I/B/E/S.Coherus biosciences inc - ‍anticipate cash use in operations of about $35 - $40 million in Q4 of 2017​.  Full Article

Coherus Biosciences says FDA acceptance of 351(K) biologics license application
Friday, 7 Oct 2016 

Coherus Biosciences : Announces FDA Acceptance Of 351(K) Biologics License Application to U.S. Food And Drug Administration for CHS-1701 (pegfilgrastim biosimilar candidate) .Biosimilar User Fee Act (BSUFA) action date is June 9, 2017.  Full Article

Coherus Biosciences regains development and commercial rights to CHS-0214 from Shire
Tuesday, 27 Sep 2016 

Coherus Biosciences Inc. : Says has regained from shire plc all development and commercial rights previously licensed for chs-0214 etanercept . Coherus Biosciences regains development and commercial rights to CHS 0214 from Shire . As result of termination agreement with Shire, co expects to recognize $162.6 million as collaboration and license revenues in 2016 . CHS-0214 etanercept is a biosimilar candidate to enbrel for Europe, Canada, Brazil, Middle East and other territories .Remain on track for submission of a CHS-0214 marketing authorization application to european medicines agency in Q4 of 2016.  Full Article

Coherus Biosciences reports Q2 2016 financial and operating results
Wednesday, 10 Aug 2016 

Coherus Biosciences Inc : Coherus Biosciences reports second quarter 2016 financial and operating results . Total revenue for Q2 of 2016 was $14.1 million, as compared to $6.9 million in Q2 of 2015 . Partnering discussions for immunology (anti-tnf) therapeutic franchise have begun, targeting an agreement in first half of 2017 . Q2 earnings per share view $-1.32 -- Thomson Reuters I/B/E/S .Qtrly loss per share $1.72.  Full Article

Coherus Biosciences announces positive topline Phase III results for CHS-1420
Monday, 8 Aug 2016 

Coherus Biosciences Inc : Coherus Biosciences announces positive topline phase three results for chs-1420 (humira® biosimilar candidate) in patients with psoriasis . Study met its primary endpoint . Full dataset through treatment period 2 will be available in Q4 2016 and included in bla submission to follow .Both CHS-1420 and Humira were similarly well tolerated with similar safety profiles in study.  Full Article

Coherus BioSciences provides update on IPRs
Monday, 13 Jun 2016 

Coherus BioSciences Inc : Received favorable decision from Patent Trial and Appeal Board related to dosing regimen for Abbvie's Humira (Adalimumab) .Coherus BioSciences provides update on IPRs.  Full Article

Coherus Biosciences prices public offering of common stock
Monday, 23 May 2016 

Coherus Biosciences Inc :Coherus prices public offering of common stock.  Full Article

Coherus announces proposed public offering of common stock
Monday, 23 May 2016 

Coherus Biosciences Inc : Says offering 3.50 million common shares .Coherus announces proposed public offering of common stock.  Full Article

Coherus Biosciences provides update on '135 IPR
Tuesday, 17 May 2016 

Coherus Biosciences Inc : Coherus Biosciences provides update on '135 IPR . Coherus Biosciences Inc - Received favorable decision from Us Patent and Trademark Office instituting co's petition for inter partes review of Abbvie's U.S. Patent 8,889,135 . Coherus Biosciences Inc - Says "Confident that this will lead to a final decision nullifying '135 patent" .Coherus Biosciences Inc - Abbvie's U.S. Patent directed to dosing regimen in which 40 MG of Humira administered subcutaneously every 13 to 15 days to treat Rheumatoid Arthritis.  Full Article

Coherus Biosciences Qtrly net loss $1.67 per share
Tuesday, 10 May 2016 

Coherus Biosciences Inc : Says total revenue for q1 2016 was $12.4 million, as compared to $5.8 million in q1 of 2015. . Qtrly net loss $1.67 per share .Coherus biosciences reports first quarter 2016 financial and operating results.  Full Article

BRIEF-Temasek Holdings (Private) Ltd ups share stake in Mastercard, Visa and Monsanto

* Temasek Holdings (Private) Ltd ups share stake in Mastercard to 923,068 class a shares from 267,006 class a shares